This material is protected by U.S. copyright law. Unauthorized reproduction is prohibited. To purchase quantity reprints,
please e-mail reprints@ons.org or to request permission to reproduce multiple copies, please e-mail pubpermissions@ons.org.
This Issue's Contributors
Gail M. Wilkes, MS, RNC, AOCN, author
coordinator at Genentech BioOncology in South San Francisco, CA. At
of "Therapeutic Options in the Management
the time the article was written, Lapka was a research coordinator in the
of Colon Cancer: 2005 Update" (p. 31), is
Clinical Trials Department at Ingalls Hospital in Harvey, IL.
an oncology nurse educator and nurse prac-
titioner at Boston Medical Center in Mas-
Bridget A. Cahill, RN, APN, MS, author
sachusetts. As a nurse practitioner, Wilkes
of "Management of Patients Who Have
has worked in gastrointestinal oncology and
Undergone Hepatic Artery Chemoembo-
has been impressed by the chemotherapeutic
lization" (p. 69), is a certified adult nurse
advances made in the adjuvant and meta-
practitioner in the gastrointestinal program
static treatment of colon cancer. She wrote
in the Department of Medicine, Division
the article as an update to a 2002 Clinical
of Hematology/Oncology, at Northwestern
Journal of Oncology Nursing article that described advances relating
Medical Faculty Foundation in Chicago, IL.
to oxaliplatin and infusional 5-fluorouracil and leucovorin.
In her current position, she manages patients
who have undergone hepatic artery chemoembolization. According
Nancy J. Washburn, MSN, APRN, BC, ANP, AOCN, NP, OCN, pri-
to Cahill, "Very little information is available to oncology nurses on
hepatocellular carcinoma and hepatic artery embolization. I believe it is
mary author of "Outpatient Genetic Risk Assessment in Women With
important for oncology nurses to understand the procedure, side effects,
Breast Cancer: One Center's Experience" (p. 49), is an oncology nurse
and management in order to serve our patients."
practitioner at the Kansas City Cancer Center (KCCC) South in Mis-
souri. In addition to teaching and seeing patients, she has always been
interested in genetics and was chosen to attend an Oncology Nursing
Pamela Hallquist Viale, RN, MS, CS, ANP,
Society Genetics Short Course in 2003. According to Washburn, "The
OCN, author of "Integrating Aprepitant
literature has shown the importance of incorporating genetics programs
and Palonosetron Into Clinical Practice: A
into practice, but not how to do it in a community-based setting." There-
Role for the New Antiemetics" (p. 77), is
fore, she attempted to "show one way to identify individuals at high
an oncology nurse practitioner at the Santa
risk for genetic mutation and to make changes in practice that will help
Clara Valley Medical Center in San Jose,
manage the patients' risk of developing cancer or assist in risk reduction
CA, and an assistant clinical professor in
for their family members." Coauthors Valerie K. Sommer, RN, MSN,
the Department of Physiological Nursing at
FNP-C, is an oncology nurse practitioner at KCCC East in Lee's Sum-
the University of California, San Francisco.
mit, MO; Sarah E. Spencer, RN, BSN, CCRC, OCN, BA, is a research
She is interested in symptom management
RN at KCCC Southwest in Overland Park, KS; Sandra K. Simmons,
in patients with cancer and has lectured on
RN, MSN, ARNP-C, AOCN, is an oncology nurse practitioner at
chemotherapy-induced nausea and vomiting (CINV) across the United
KCCC West in Missouri; Barbara W. Adkins, BSN, MSN, ARNP-C,
States. With new antiemetics to help combat CINV, Viale is committed
AOCN, is a nurse practitioner at KCCC Southwest; Mary R. Rogers,
to educating oncology nurses about advances in CINV management.
RN, CS, FNP, is a nurse practioner at KCCC East; Patty L. Gerken,
MSN, ANP, OCN, AOCN, is a nurse practitioner at KCCC South;
Maribeth Hohenstein, RN, BSN, OCN, CCRC, author of "Patient-
and Christina M. Bromley, BS, MS, PhD, is the president of BioStat
Specific Vaccine Therapy for Non-Hodgkin Lymphoma" (p. 85), is a
Solutions in Mt. Airy, MD.
research nurse coordinator in the Section of Hematology and Oncology
at the University of Nebraska Medical Center in Omaha, where she
Paula J. Franson, RN, MS, AOCN, primary
coordinates care and manages protocols with investigational drugs for
patients with lymphoma. Because of her position as a research nurse,
author of "Antivascular Endothelial Growth
she has had the opportunity to work with many different novel thera-
Factor Monoclonal Antibody Therapy: A
pies for lymphoma. "Vaccines for lymphoma are fascinating and one
Promising Paradigm in Colorectal Cancer" (p.
of the more encouraging new therapies I've worked with," she said.
55), is a hematology medical science liaison
"Targeted therapies have provided safe and effective treatment options
for Genentech, Inc., in San Francisco, CA.
for our patients." Coauthors Susan E. King, RN, MS, OCN, is medical
At the time the article was written, she was
a clinical research nurse at Rush University
science liaison at Genitope Corporation in Redwood City, CA; Jennifer
Medical Center in Chicago, IL, where she had
M. Fiore, RN, MA, ANP-C, is a nurse practitioner with the Division of
firsthand experience with new targeted agents,
Hematology and Medical Oncology in Weill Medical College at Cor-
nell University in New York, NY; Teresa O'Brien, RN, BSN, OCN, is
including antivascular endothelial growth factor. According to Franson,
"New agents such as bevacizumab are promising additions to our an-
coordinator of research nurses in the Section of Hematology/Oncology
ticancer weaponry, highlighting a more powerful trend--the targeting
at Rush University Medical Center in Chicago, IL; and Susan Blumel,
RN, BSN, OCN, CCRC, is a clinical research nurse coordinator in
of the molecular mechanism underlying the disease process--that will
maximize outcomes and quality of life for patients with cancer." Coau-
the Section of Hematology and Oncology at the University of Nebraska
thor Denise V. Lapka, RN, MS, AOCN, CCNS, is an oncology clinical
Medical Center.